Clinical trial
Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in…
NCT01322347 · Rockwell Medical Technologies, Inc., Industry · Completed
Key facts
| NCT number | NCT01322347 |
|---|---|
| Title | Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients (CRUISE 2) |
| Official title | A Randomized, Placebo-Controlled, Phase III Study of Dialysate Containing Soluble Ferric Pyrophosphate (SFP) in Chronic Kidney Disease Patients Receiving Hemodialysis: The Continuous Replacement Using Iron Soluble Equivalents (CRUISE 2) Study |
| Lead sponsor | Rockwell Medical Technologies, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Renal Failure Chronic Requiring Hemodialysis |
| Intervention type | Device, Drug |
| Interventions | Soluble Ferric Pyrophosphate (SFP), Standard dialysate |
| Enrollment | 294 |
| Start date | Apr 1, 2011 |
| Primary completion | Jan 1, 2014 |
| Completion | Feb 1, 2014 |
| First posted | Mar 24, 2011 |
| Last update posted | Apr 26, 2017 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: